Mark A. Turco, MD, FACC

The TAXUS ATLAS Trial: Workhorse lesions and direct stenting with the Libert© paclitaxel-eluting stent

06/19/2008

It has a new five-fold balloon design that will likely decrease any of the previous withdrawal resistances recognized in the previous platform by some operators. The uniform cell geometry of the Libert© stent hopefully allows for more...

It has a new five-fold balloon...

06/19/2008

Cath Lab Digest

Feature

High-Risk Coronary Lesions Simulation Training

06/19/2008

Mark A. Turco , MD, FACC;

Dr. Turco, there’s an increasing focus on simulation training. Could you describe simulation training and why it’s becoming more widely used? Simulation training provides hands-on training in a true-to-life but risk-free environment with...

Dr. Turco, there’s an increasing...

06/19/2008

Cath Lab Digest

Feature

Drug-Eluting Stent Solutions: The Continuing Evolution of Drug-Eluting Stents

06/19/2008

Mark A. Turco , MD, FACC;

Mark A. Turco, MD, FACC, FSCAI is an interventional cardiologist who is the Director of the Center of Cardiac & Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. He has significant experience in clinical trial...

Mark A. Turco, MD, FACC, FSCAI...

06/19/2008

Cath Lab Digest

The Anticoagulant Therapy with Bivalirudin to Assist in the <br />
Performance of Percutaneous Coronary Intervention in Patients with

08/01/2008

Mark A. Turco , MD, FACC;

Yoseph Shalev , MD;

Peter Ver Lee , MD;

A. Ralph Rodriguez , MD;

E. Magnus Ohman , MD;

Robert A. Harrington , MD;

Robert M. Califf , MD;

Jay H. Traverse , MD;

Kenneth W. Mahaffey , MD;

Bruce E. Lewis , MD;

Nancy M. Wildermann , BA;

Scott D. Berkowitz , MD;

Renee M. Oliverio , RN;

Heparin-induced thrombocytopenia (HIT) is infrequent and often goes unrecognized. It occurs in ~1% to 5% of the patients given unfractionated heparin,1 about 25–50% of whom will develop HIT with thrombotic syndrome (HITTS).2 Morbidity and...

Heparin-induced thrombocytopenia...

08/01/2008

Journal of Invasive Cardiology

High-Risk Coronary Lesions Simulation Training

06/19/2008

Mark A. Turco , MD, FACC;

Dr. Turco, there’s an increasing...

06/19/2008

Cath Lab Digest

Drug-Eluting Stent Solutions: The Continuing Evolution of Drug-Eluting Stents

06/19/2008

Mark A. Turco , MD, FACC;